CN1456350A - Eye cyclosporin gel - Google Patents

Eye cyclosporin gel Download PDF

Info

Publication number
CN1456350A
CN1456350A CN 02117619 CN02117619A CN1456350A CN 1456350 A CN1456350 A CN 1456350A CN 02117619 CN02117619 CN 02117619 CN 02117619 A CN02117619 A CN 02117619A CN 1456350 A CN1456350 A CN 1456350A
Authority
CN
China
Prior art keywords
gel
eye
ciclosporin
methyl
ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 02117619
Other languages
Chinese (zh)
Inventor
刘继东
姚东民
高峨
宋长海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 02117619 priority Critical patent/CN1456350A/en
Publication of CN1456350A publication Critical patent/CN1456350A/en
Pending legal-status Critical Current

Links

Images

Abstract

A cyclosporin eye gel for treating the rejection reaction of corneal transplantation, keratoconjunctival xerosis, catarrhal conjunctivitis, and chemical burn of eye is prepared from cyclosporin, boric acid, borax, trichloro-tert-butanol, etc. Its advantages are long stay time in eye and high curative effect.

Description

Eye cyclosporin gel
Affiliated technical field
---ciclosporin---makes gel for eye use first to the present invention relates to a kind of effective ingredient, be applied to the treatment of ocular disease, the following ophthalmic diseases of main treatment: 1, corneal allograft rejection, 2, corneal and conjunctival xerosis (KC), 3, vernal conjunctivitis, 4, eye chemical burn (2 degree to 4 degree).
Background technology
At present, ciclosporin ophthalmology preparation at home and abroad hospital uses in a large number, is hospital preparation, does not see launch.It is clinical that the U.S. was carrying out for three phases, domesticly declares eye drip oil preparation person.There is no the person that declares the eye cyclosporin gel both at home and abroad.
Summary of the invention
Big in order to overcome dosage, oral drugs are difficult to the deficiency by blood-eye barrier, invent a kind of gel for eye use, the ophthalmology topical, not only solved eye drop and easily diluted by tear, the problem that the ophthalmic time of staying is short, and use amount is few, improve the bioavailability of effective ingredient, increase curative effect and drug safety.
Technical scheme of the present invention is: the ciclosporin ingredient forms stable transparent mastic with card pool nurse mastic substrate, uses the back and forms the gas-pervious reticular membrane of one deck at the eye table, and effect is lasting.Its concrete feature is as follows:
The eye cyclosporin gel single preparations of ephedrine, its general eye cyclosporin gel by name; Chemistry ring by name [[(E)-(2S, 3R, 4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octene acyl]-the amino butyryl of L-2-N-methyl glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl] gel for eye use; English CiclosporinOphthalmic Gel by name; The Chinese phonetic alphabet is Huanbaosu Yanyong Ningjiao; Medicine and main adjunct ingredient and the preparation of forming in following ratio that is applied to ophthalmology illness thereof: wherein containing ciclosporin is 2.0% (w/w), containing card pool nurse is 0.4% (w/w), borax is 1.0% (w/w), and boronic acid containing is 0.5% (w/w), and containing chlorobutanol is 0.3% (w/w); Be applied to the treatment of corneal allograft rejection, cornea and conjunctiva xerosis (KC), vernal conjunctivitis, eye chemical burn ophthalmology illness such as (2 degree are to 4 degree); Its preparation process is: the chlorobutanol of getting recipe quantity soaks carbomer wherein with the dissolving of 900ml water for injection, spends the night.Borax, the boric acid of getting recipe quantity add wherein, stir, and make clear gel substrate; The recipe quantity ciclosporin is ground into impalpable powder, crosses sieve No. 9, gradation is ground in the substrate under the heating condition, and moisturizing stirs to full dose; Filter with 220 mesh sieve cloth, pressure sterilizing, packing, promptly.In addition, substrate such as effective ingredient and hydroxypropyl methylcellulose series, methylcellulose series, polyvinyl alcohol series all can form gel, and card pool nurse series substrate effect is best.Among the above-mentioned preparation technology, its core technology is: (1) ciclosporin ingredient grinds to form impalpable powder (crossing sieve No. 9), (2) grinding heating (temperature range 60-80 ℃) mixed dissolution with adjunct ingredient is to guarantee the transparent key of mastic, (3) card pool nurse swelling (concentration range 0.5-5.0%) is made transparent emulsifiable paste, (4) pressure sterilizing (115 ℃, 30 minutes).
Good effect of the present invention: the development of eye cyclosporin gel and exploitation have following advantage: (1), eye cyclosporin gel directly act on the affected part, can play a role fully effectively, can reduce GI irritation and other side effect that oral drugs cause.(2), with respect to other ophthalmic preparation, gel has unrivaled advantage.Compare eye cyclosporin gel with eye drop and be difficult for being diluted by tear, within the eye the time of staying long, help main abundant absorption and utilization; Compare with the eye ointment of vaseline substrate, the eye cyclosporin gel good water solubility is cleaned easily, and pollution clothes is not easy to use.On the other hand, eye cyclosporin gel does not cause the visual field fuzzy, uses the back to form the gas-pervious reticular membrane of one deck at the eye table, all can use round the clock.This Products Development is successful, not only can fill up a blank of domestic ophthalmic remedy, also can bring good social benefit and economic benefit.(3), our enterprise is the ophthalmic remedy manufacturer of domestic specialty, is devoted to production, development, the exploitation of medicament for the eyes over more than 30 year always, actively participates in work for the public good, ophthalmic remedy accounts for more than 90% of the gross output value.
Embodiment
Prescription 1: ciclosporin 2.0g
Card pool nurse 0.4g
Borax 1.0g
Boric acid 0.5g
Chlorobutanol 0.3g
Make the 100.0g operating process:
2.. Borax, boric acid are made clear gel substrate in adding 1..
3.. ciclosporin grinds to form impalpable powder, crosses sieve No. 9, during 2. gradation grinds under the heating condition.
4. .220 mesh sieve cloth filters, pressure sterilizing, and packing, packing, promptly.
Prescription 2: ciclosporin 0.5-10.0g
Card pool nurse 0-4.0g
Borax 0-10.0g
Boric acid 0-5.0g
Chlorobutanol 0-3.0g
Make the 100.0g operating process:
1.. suitable quantity of water, the dissolving chlorobutanol adds the dissolving of card pool nurse, spends the night.
2.. Borax, boric acid are made clear gel substrate in adding 1..
3.. ciclosporin grinds to form impalpable powder, crosses sieve No. 9, during 2. gradation grinds under the heating condition.
4. .220 mesh sieve cloth filters, pressure sterilizing, and packing, packing, promptly.Creativeness of the present invention realizes by clinical, toxicology and pharmacology data, provides in the lump during examination as to substances.
Fig. 1 is an eye cyclosporin gel preparation technology flow chart.

Claims (2)

1. one kind is used for the eye cyclosporin gel single preparations of ephedrine that corneal allograft rejection, cornea and conjunctiva xerosis (KC), vernal conjunctivitis, eye chemical burn (2 degree are to 4 degree) wait ophthalmology illness to treat, its general eye cyclosporin gel by name; Chemistry ring by name [[(E)-(2S, 3R, 4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octene acyl]-the amino butyryl of L-2-N-methyl glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl] gel for eye use; English Ciclosporin Ophthalmic Gel by name; The Chinese phonetic alphabet is Huanbaosu Yanyong Ningjiao; Medicine and main adjunct ingredient and the preparation of forming in following ratio that is applied to ophthalmology thereof: wherein containing ciclosporin is 2.0% (w/w), containing card pool nurse is 0.4% (w/w), borax is 1.0% (w/w), and boronic acid containing is 0.5% (w/w), and containing chlorobutanol is 0.3% (w/w); Preparation process: the chlorobutanol of getting recipe quantity soaks carbomer wherein with the dissolving of 900ml water for injection, spends the night.Borax, the boric acid of getting recipe quantity add wherein, stir, and make clear gel substrate; The recipe quantity ciclosporin is ground into impalpable powder, crosses sieve No. 9, gradation is ground in the substrate under the heating condition, and moisturizing stirs to full dose; Filter with 220 mesh sieve cloth, pressure sterilizing, packing, promptly.In addition, substrate such as ciclosporin effective ingredient and hydroxypropyl methylcellulose series, methylcellulose series, polyvinyl alcohol series all can form gel, and card pool nurse series substrate effect is best.Among the above-mentioned preparation technology, its core technology is: (1) ciclosporin ingredient grinds to form impalpable powder (crossing sieve No. 9), (2) grinding heating (temperature range 60-80 ℃) mixed dissolution with adjunct ingredient is to guarantee the transparent key of mastic, (3) card pool nurse swelling (concentration range 0.5-5.0%) is made transparent emulsifiable paste, (4) pressure sterilizing (115 ℃, 30 minutes).
2. according to the described eye cyclosporin gel of claim 1, it is characterized in that this effective ingredient ciclosporin makes gel for eye first, medicine and main adjunct ingredient and the preparation of forming in following ratio that is applied to the ophthalmology illness treatment thereof: wherein ciclosporin is its active ingredient, concentration is 0.5-10.0% (w/w), it is 0-4.0% (w/w) that main adjuvant contains card pool nurse, borax is 0-10.0% (w/w), boronic acid containing is 0-5.0% (w/w), and containing chlorobutanol is 0-3.0% (w/w).
CN 02117619 2002-05-10 2002-05-10 Eye cyclosporin gel Pending CN1456350A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 02117619 CN1456350A (en) 2002-05-10 2002-05-10 Eye cyclosporin gel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 02117619 CN1456350A (en) 2002-05-10 2002-05-10 Eye cyclosporin gel

Publications (1)

Publication Number Publication Date
CN1456350A true CN1456350A (en) 2003-11-19

Family

ID=29410324

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 02117619 Pending CN1456350A (en) 2002-05-10 2002-05-10 Eye cyclosporin gel

Country Status (1)

Country Link
CN (1) CN1456350A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7833966B2 (en) 2005-07-18 2010-11-16 Peyman Gholam A Enhanced ocular neuroprotection and neurostimulation
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8367097B2 (en) 2005-02-09 2013-02-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CN103656617A (en) * 2012-09-26 2014-03-26 沈阳兴齐眼药股份有限公司 Preparation method of ciclosporin ophthalmic solution
CN103735495A (en) * 2014-01-23 2014-04-23 兆科药业(合肥)有限公司 Ciclosporin eye gel and preparation method thereof
CN104039308A (en) * 2011-11-15 2014-09-10 阿勒根公司 Autoclavable suspensions of cyclosporin a form 2

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US9387165B2 (en) 2005-02-09 2016-07-12 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US9381153B2 (en) 2005-02-09 2016-07-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8367097B2 (en) 2005-02-09 2013-02-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8927005B2 (en) 2005-02-09 2015-01-06 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8202840B2 (en) 2005-07-18 2012-06-19 Minu L.L.C. Enhanced ocular neuroprotection and neurostimulation
US7833966B2 (en) 2005-07-18 2010-11-16 Peyman Gholam A Enhanced ocular neuroprotection and neurostimulation
US8658667B2 (en) 2006-02-09 2014-02-25 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8486960B2 (en) 2006-03-23 2013-07-16 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US9452156B2 (en) 2006-03-23 2016-09-27 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CN104039308A (en) * 2011-11-15 2014-09-10 阿勒根公司 Autoclavable suspensions of cyclosporin a form 2
CN104039308B (en) * 2011-11-15 2018-06-05 阿勒根公司 The hot pressing suspension of cyclosporin A form 2
CN108714137A (en) * 2011-11-15 2018-10-30 阿勒根公司 The hot pressing suspension of cyclosporin A form 2
CN108714137B (en) * 2011-11-15 2022-02-01 阿勒根公司 Thermostatible suspension of cyclosporin A form 2
CN103656617A (en) * 2012-09-26 2014-03-26 沈阳兴齐眼药股份有限公司 Preparation method of ciclosporin ophthalmic solution
CN103735495A (en) * 2014-01-23 2014-04-23 兆科药业(合肥)有限公司 Ciclosporin eye gel and preparation method thereof

Similar Documents

Publication Publication Date Title
CN101716214B (en) Medical composition containing dandelion extract as well as novel application and preparation method thereof
CN1456350A (en) Eye cyclosporin gel
CN101648004A (en) Medicinal composition for treating eye diseases and application thereof
CN108186733A (en) A kind of pharmaceutical gel patch and its preparation method and application
CN104474009A (en) Eye cleaning liquid and preparation method thereof
CN111558031B (en) Pure plant multifunctional eye special nutrient solution and preparation method thereof
CN101284048A (en) Formulations for effectively improving hypometropia, asthenopia, cataract, eyeground pathological changes
CN1456161A (en) Eye gel for atropine sulfate
CN102166205A (en) New medical application of paeonol and derivatives thereof
CN102579599B (en) Decumbent corydalis tuber eye drop and preparation method thereof
CN102512467A (en) Ophthalmic preparation of panax notoginseng saponins and preparation method thereof
CN1194685C (en) Ophthalmic gel of marticarpine
CN1132584C (en) Myopia treating eye drop
CN106073363B (en) Chrysanthemum fragrance pillow with remarkable curative effect on myopia
CN1180776C (en) Ofloxacin eye ointment
CN1311842C (en) Medicine for treating chronic conjunctivitis
CN1456157A (en) Ophthalmic gel of L-ofloxacin
CN113413415A (en) Lanosterol eye drops and preparation method thereof
CN110123880A (en) A kind of Chinese medicine eye refreshing drop and preparation method thereof
CN1285363C (en) Chinese and western compound medicinal eye drop for quick treatment of eyeball congestion disease
JPS63174935A (en) Lysozyme-containing medicinal-cosmetic composition
CN110269895A (en) A kind of visual rehabilitation Chinese medicine composition containing fresh Chinese medicine and preparation method thereof, preparation
CN1170562C (en) Medicine for treating tinea
CN100387260C (en) Eye medicine for treating senile cataract and its pH value regulating method and preparing process
CN105920060A (en) Medicine composition containing iodized lecithin and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication